Diagnostic value of 18F-FDG PET in the assessment of myocardial viability in coronary artery disease: A comparative study with 99mTc SPECT and echocardiography by Al Moudi, M. & Sun, Zhonghua
 Journal of Geriatric Cardiology (2014) 11: 18 
 ©2014 JGC All rights reserved; www.jgc301.com 
  
http://www.jgc301.com; jgc@jgc301.com | Journal of Geriatric Cardiology 
Research Article     Open Access  
 
Diagnostic value of 
18
F-FDG PET in the assessment of myocardial viability in 
coronary artery disease: A comparative study with 
99m








1Department of Medical Imaging and Nuclear Medicine, King Saud Medical City, Riyadh, Saudi Arabia 
2Discipline of Medical Imaging, Department of Imaging and Applied Physics, Curtin University, GPO Box U1987 Perth, Western Australia 6845, Australia 
 
Abstract 
Objectives  To investigate the diagnostic value of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in the as-
sessment of myocardial viability in patients with known coronary artery disease (CAD) when compared to 99mTc single photon emission 
computed tomography (SPECT) and echocardiography, with invasive coronary angiography as the gold standard. Methods  Thirty patients 
with diagnosed CAD met the selection criteria, with 10 of them (9 men, mean age 59.5 ± 10.5 years) undergoing all of these imaging proce-
dures consisting of SPECT and PET, echocardiography and invasive angiography. Diagnostic sensitivity of these less invasive modalities for 
detection of myocardial viability was compared to invasive coronary angiography. Inter- and intra-observer agreement was assessed for di-
agnostic performance of SPECT and PET. Results  Of all patients with proven CAD, 50% had triple vessel disease. Diagnostic sensitivity 
of SPECT, PET and echocardiography was 90%, 100% and 80% at patient-based assessment, respectively. Excellent agreement was 
achieved between inter-observer and intra-observer agreement of the diagnostic value of SPECT and PET in myocardial viability (k = 0.9). 
Conclusions  
18F-FDG PET has high diagnostic value in the assessment of myocardial viability in patients with known CAD when com-
pared to SPECT and echocardiography. Further studies based on a large cohort with incorporation of 18F-FDG PET into patient management 
are warranted. 
J Geriatr Cardiol 2014; 11: 18. doi: 10.11909/j.issn.1671-5411.2014.03.008 







Cardiac positron emission tomography (PET) utilizing 
18F-fluorodeoxyglucose (18F-FDG) is considered the most 
sensitive modality for detecting hibernating viable myocar-
dium and predicting left ventricular functional recovery 
post-coronary revascularization.[1–4] 18F-FDG PET imaging 
has been reported to show incremental benefit over 201T1 
stress-redistribution/reinjection or 99mTc-sestamibi single 
photon emission computed tomography (SPECT) in pre-
dicting functional recovery in the patients with significantly 
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impaired left ventricular function, while in patients with 
relatively preserved left ventricular function, the predictive 
value was similar.[5,6] Tillisch, et al.[1] in their first pioneer-
ing study reported the value of 18F-FDG PET to predict re-
versibility of cardiac wall motion abnormalities in 17 pa-
tients with ischemic cardiomyopathy. The overall sensitivity 
and specificity of 18F-FDG PET to demonstrate functional 
recovery after surgery was 95% and 80%, respectively. A 
meta-analysis of 24 studies has reported a weighted sensi-
tivity and specificity of 92% and 63%, respectively, with a 
positive and negative predictive value of 74% and 87%, 
respectively, for the diagnosis of hibernating myocardium 
and prediction of patient outcomes.[2] 
In addition to cardiac PET, there are other diagnostic 
imaging techniques that are also commonly used to deter-
mine myocardial viability such as SPECT, cardiac magnetic 
resonance imaging (MRI) and echocardiography. The diag-
nostic accuracy of 18F-FDG PET compares well with other 
established techniques for viability assessment (SPECT, 
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echocardiography, and cardiac MRI), with sensitivity being 
superior to other techniques, although cardiac PET is not as 
widely available as other techniques.[3] A previous health 
technology assessment identified the pooled estimates of 
sensitivity and specificity of 18F-FDG PET for predicting 
wall motion recovery to be 91.5% and 67.8%, respective-
ly.[4] 
Despite these promising results, there is still a lack of 
scientific data with regard to the diagnostic value of cardiac 
PET in the evaluation of myocardial viability.[7] Thus, the 
purpose of this study is to investigate the diagnostic accura-
cy of 18F-FDG PET in the assessment of myocardial viabil-
ity in patients with known coronary artery disease (CAD) 
when compared to the routinely performed 99mTc-tetrofos-
min SPECT and echocardiography while using invasive 
coronary angiography as the gold standard. We hypothe-
sized that 18F-FDG PET is superior to SPECT and echocar-
diography in the diagnostic evaluation of myocardial viabil-
ity. 
2. Methods 
2.1 Study population 
This was a prospective study that involved consecutive 
recruitments of patients with previous history of myocardial 
infarction and left ventricular dysfunction over a period of 6 
months at the National Heart Institute, Malaysia and Un-
iversiti Kebangsaan Malaysia Medical Centre. All patients 
were suggested to undergo cardiac SPECT, cardiac PET 
myocardial viability, echocardiography and invasive coro-
nary angiography examinations with an interval of less than 
30 days between the imaging tests. Exclusion criteria in-
cluded patients with suspected CAD but clinically con-
firmed to be non-ischemic left ventricular dysfunction, pa-
tients refused to participate in the study and patients with 
pregnancy. Thirty patients met the selection criteria, how-
ever, only ten patients (9 men; mean age 59.5 ± 10.5 years) 
agreed to participate in the study and eventually underwent 
all of these imaging procedures consisting of invasive coro-
nary angiography, echocardiography, cardiac SPECT and 
PET. Consent forms were obtained from all patients, and 
ethical approval was granted from institutional review 
boards. 
2.2 Invasive coronary angiography and image assess-
ment 
Coronary angiography was carried out using the standard 
Seldinger’s technique on an angiographic machine by fe-
moral approach which was performed by cardiologists at the 
National Heart Institute, Malaysia. A cardiologist with more 
than 10 years of experience who had no prior knowledge of 
cardiac SPECT or PET findings quantitatively analysed the 
severity of coronary stenosis. The minimal lumen diameter 
was measured in projections showing the most severe nar-
rowing. 
The degree of stenosis was classified into four categories: 
(1) no stenosis, (2) minimal or mild stenosis (≤ 50%), (3) 
moderate stenosis (50%–70%), and (4) severe stenosis (> 
70%). CAD was defined when lumen diameter reduction 
was greater than 50% (moderate or severe stenosis). 
2.3 Echocardiography and quantitative image assess-
ment 
Dobutamine echocardiography was performed by a car-
diologist (with more than 10 years of experience in cardiac 
imaging) using a standard protocol. First, resting echocar-
diography was achieved with the patient placed in the left 
lateral leaning position. Echocardiographic imaging was 
then completed through an intravenous infusion of dobuta-
mine, first at a dose of 5 μg/kg per minute, then it was in-
creased at every 3 min to 7.5, 10, 20, 30, and 40 μg/kg per 
minute, respectively. Images were acquired in the normal 
parasternal long-axis and short-axis views, with particular 
attention paid to determining the regional cardiac function. 
Through dobutamine infusion, the 12-lead electrocardio-
graph (ECG) and blood pressure were observed every 
minute. The cardiologist was blinded to the results of other 
imaging modalities. 
Calculations of the regional wall motion were assumed 
off line using a 16-segment model according to the Ameri-
can Society of Echocardiography.[7–9] These 16 segments 
were classified as 0 = normal; 1 = hypokinetic; 2 = akinetic; 
and 3 = dyskinetic. Only segments within the infarc-
tion-related coronary segment were analyzed for wall mo-
tion. From this territory, the regional wall motion score was 
calculated. 
2.4 Cardiac SPECT and quantitative image assessment 
All patients underwent a gated-SPECT 99mTc tetrofosmin 
(GE Ventri, GE Healthcare, Florida, USA). After a mini-
mum of 4 h of fasting, nitrates were stopped for 12 h prior 
to the study. Following intravenous cannulation, 450 MBq 
(12 mCi) of 99mTc tetrofosmin was administered intrave-
nously under resting conditions. About 45–60 min after 
radiotracer injection, a resting SPECT study was performed 
under double-headed gamma camera equipped with 
high-resolution collimators. Data were acquired in 64 × 64 
matrix, with 32 projections, and 8 frames per cardiac cycle, 
and were used in association with a 20% window centred on 
the 140-keV photon peak. 
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All data of the 99mTc-tetrofosmin SPECT studies were 
reoriented into short-axis and horizontal and vertical 
long-axis sections. Quantitative analysis was performed 
using a commercially available gated-cardiac software 
package (4D-MSPECT; University of Michigan Medical 
Center) for assessing left ventricular regional wall motion.[10] 
The left ventricular wall motion was visually classified into 
4 categories (0 = normal, 1 = mild hypokinetic, 2 = mod-
erate or severe hypokinetic, and 3 = akinetic or dyskinetic) 
using a 17-segment model. 
2.5 Cardiac PET and quantitative image assessment 
All of the patients were informed of fasting for at least 6 
h before the scan and baseline blood sugar was checked. 
About 45–60 min after injection of the 50–75 g of glucose 
loading, blood sugar was checked. If it was < 140 mg/dL, 
444 MBq (12 mCi) of 18F-FDG was injected intravenously. 
If it was > 140 mg/dL, regular insulin was injected intrave-
nously according to blood glucose level (2, 3 and 5 U of 
regular insulin for 140–160, 160–180, and 180–200 mg/dL 
of blood glucose, respectively). About 45–60 min after 
18F-FDG injection myocardial 18F-FDG PET study was 
performed in a PET scanner in a 3D mode (Siemens Medi-
cal Systems, Erlangen, Germany). PET acquisition parame-
ters were as follows: myocardium was covered in one bed 
position (5 min per bed position) with ECG gating (8 
frames/RR cycle). 
The American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines 
(ACC/AHA/ASNC) recommend a semi-quantitative analy-
sis of PET studies based on a validated segmental scoring 
system.[11,12] A 17-segment model analysis was proposed 
using a 5-point scale system in direct proportion to the ob-
served count density of the segment: 0 = normal perfusion, 
1 = mild defect, 2 = moderate defect, 3 = severe defect and 
4 = absent uptake. 
2.6 Cardiac SPECT, PET and echocardiogra-
phy-qualitative image assessment 
The data were independently analyzed by two radiolo-
gists (with more than 10 years of experience in cardiac im-
aging). Both radiologists used a 17-segment model to ana-
lyze myocardial viability as observed on SPECT and PET 
images and analysis was based on a 5-point scale examining 
the segment of three main coronary arteries, namely: left 
anterior descending (LAD), left circumflex (LCX) and right 
coronary artery (RCA): 0 = normal perfusion, 1 = mild de-
fect, 2 = moderate defect, 3 = severe defect and 4 = absent 
uptake. For echocardiography, the assessment used was 
according to the 16-segment model as recommended by the 
American Society of Echocardiography. 
2.7 Statistical analysis 
All data were entered into SPSS V 20.0 for statistical 
analysis (SPSS, Chicago, ILL). Continuous variables were 
expressed as mean ± SD, while categorical variables were 
presented as percentages. P < 0.05 was considered statisti-
cally significant difference.  
Agreement in qualitative measurements between two ra-
diologists (both intra- and inter-observer variability) and 
between different methods was compared using kappa sta-
tistics (κ) and classified as follows: poor (κ = 0.20); fair (κ = 
0.21–0.40); moderate (κ = 0.41–0.60); good (κ = 0.61–0.80) 
and excellent agreement (κ = 0.81–1.00). Echocardiography, 
99mTc tetrofosmin SPECT and 18F-FDG PET were calcu-
lated for diagnostic value when compared to invasive coro-
nary angiography which was regarded as the gold standard. 
3  Results 
A total of 10 patients were included in this study and pa-
tient’s characteristics are shown in Table 1. All patients had 
proven CAD but in 50% of the patients the principal diag-
nosis had triple vessel disease involving LAD, LCX and  
Table 1.  Patient demographics (n = 10). 
Age, yrs 59.5 ± 10.5 
Male/Female 9/1 
Principal diagnosis (%) 
Ischaemic heart disease 
Ischemic dilated cardiomyopathy   
Inferior STEMI thrombolysed 
Two vessel disease 
Triple vessel disease 




















Patient management (%) 
Control risk factors 
Referral for coronary bypass surgery 
Percutaneous coronary intervention 
Implantable cardioverter defibrillator 
Medical therapy 








STEMI: ST segment elevation myocardial infarction. 
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RCA with ≥ 50% stenosis. A total of 340 segments in 10 
patients were analysed for cardiac SPECT and PET imaging 
examinations, while for echocardiography there were 160 
segments that were analyzed in comparison with cardiac 
SPECT and PET findings. 
3.1 Diagnostic accuracy at per-patient assessment 
The diagnostic sensitivity of cardiac SPECT, PET and 
echocardiography at per-patient assessment was 90%, 100% 
and 80% respectively, as shown in Figure 1. Since all pa-
tients had confirmed CAD, specificity was not analysed 
(true negative value was zero). 
 
Figure 1. Diagnostic sensitivity of PET, SPECT and echocar-
diography in myocardial viability when compared to invasive 
coronary angiography at per-patient based assessment. Echo: 
echocardiography; PET: positron emission tomography; SPECT: 
single photon emission computed tomography. 
3.2 Diagnostic accuracy at per-vessel assessment 
Comparison was also performed between the cardiac 
PET and SPECT according to vessel-based assessment, as 
shown in Figure 2. Of the 30 coronary arteries (LAD, LCX, 
and RCA), 22 were found to have significant coronary ste-
nosis or occlusion (> 70% lumen stenosis), with mild to 
moderate stenosis observed in 6 coronary arteries on inva-
sive coronary angiography. Of these diseased coronary arte-
ries, 8 were found in the LAD and LCX, and 6 in the RCA. 
Interestingly, for 2 patients documented mild to moderate 
coronary stenosis by invasive coronary angiography, the 
three functional modalities, echocardiography, SPECT and 
PET all showed abnormal changes with PET revealing se-
verely reduced FGD uptake in different regions. Results 
showed that cardiac PET has the highest diagnostic value in 
the assessment of all of the three main coronary arteries, 
while SPECT has moderate diagnostic value in LAD, but 
low diagnostic performance in the other two coronary arte-
ries, RCA and LCX. 
 
Figure 2. Diagnostic sensitivity of SPECT and PET in myocar-
dial viability at per-vessel based assessment. As shown in the 
figure, diagnostic value of PET is superior to that of SPECT in the 
all of the three main coronary arteries. LAD: left anterior descend-
ing; LCX: left circumflex; PET: positron emission tomography; 
RCA: right coronary artery; SPECT: single photon emission com-
puted tomography. 
3.3 Qualitative image assessment by echocardiography, 
SPECT and PET 
The mean score for assessment of cardiac function and 
myocardial viability by echocardiography, SPECT and PET 
at per-patient based analysis was 2.8 ± 0.42, 3.8 ± 0.63, 4.0, 
respectively. The ejection fraction of left ventricle measured 
by echocardiography was less than 40% in all of the patients, 
while the corresponding SPECT and PET scans showed 
severely reduced and no uptake of radiopharmaceuticals in 
more than 80% of the patients. 
The mean score for assessment of myocardial viability 
by SPECT and PET at per-vessel based analysis was 3.4 ± 
0.96 and 3.6 ± 0.84, 2.5 ± 1.64 and 3.8 ± 0.42, 2.9 ± 1.28 
and 4.0, corresponding to the LAD, LCX and RCA coro-
nary arteries, respectively. The inter-observer assessment, 
namely SPECT observer 1, SPECT observer 2, PET observer 1 and 
PET observer 2 were analyzed with regard to the diagnostic 
evaluation of myocardial viability. Results showed that PET 
observer1 has high diagnostic value, while the diagnostic per-
formance of PET observer 2 is the same as SPECT observer 1 and 
SPECT observer 2, although this did not reach significant dif-
ference. Excellent agreement was reached on the sensitivity 
of PET observer 1 and PET observer2, SPECT observer 1 and  
SPECT observer 2 with kappa value of 0.9. 
Figure 3 is an example of cardiac SPECT imaging in a 
patient diagnosed with significant CAD, while Figure 4 is 
another example of cardiac PET imaging in the same patient 
with CAD. Both cardiac SPECT and PET detected abnor-
mal myocardial changes, although cardiac PET is superior 
to cardiac SPECT in terms of image quality with more ac-
curate assessment of all of the segments. 
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Figure 3. Gated 
99m
T-tetrofosmin SPECT viability imaging shows marked reduced myocardial thickening and akinetic wall motion 
at the apex, anterior apical, anteroseptal mid and inferior mid segments. SPECT: single photon emission computed tomography. 
 
Figure 4. Gated 
18
F-FDG PET viability imaging shows severely reduced 
18
FDG uptake in the inferior apical, inferior mid and infe-
rior basal segments. 
18F-FDG PET: 18F-fluorodeoxyglucose positron emission tomography. 
4 Discussion 
This prospective study investigates the diagnostic value 
of non-invasive cardiac modalities through comparing 
18F-FDG PET with 99mTc tetrofosmin SPECT and echocar-
diography with the aim of determining myocardial viability 
in patients with known CAD with invasive coronary angio-
graphy as the gold standard. Our results showed that cardiac 
18F-FDG PET has superior diagnostic value in patients with 
CAD, when compared to SPECT and echocardiography 
either at per-patient or per-vessel based analysis. Although 
based on a small number of patients, results of this study 
highlight the high diagnostic value of 18F-FDG PET in the 
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detection of myocardial viability. 
The assessment of myocardial viability with 18F-FDG 
PET is based on its ability to distinguish the two main pa-
thogenic mechanisms for chronic myocardial dysfunction in 
ischemic cardiomyopathy: irreversible loss of myocardium 
due to prior myocardial infarction (scar), and at least par-
tially reversible loss of contractility owing to chronic or 
repetitive ischemia (hibernating myocardium).[2] The dis-
tinctive feature of these two mechanisms is that revascula-
rization has the potential to restore contractile function of 
the hibernating myocardium but not scar.[13] This distinction 
may be of paramount importance in clinical deci-
sion-making because of the upfront morbidity and mortality 
associated with revascularization procedures in patients with 
severe left ventricular dysfunction. 
Our results are consistent with previous findings which 
reported the high diagnostic accuracy of 18F-FDG PET in 
viability assessment, and 18F-FDG PET compares well with 
other established techniques such as SPECT and echocar-
diography.[14–17] Studies using 18F-FDG PET suggested that 
the presence of viable myocardium by itself carries an in-
creased risk for adverse events compared to patients without 
viable myocardium.[18–20] In a recent meta-analysis, the op-
timal threshold for the presence of viability required to im-
prove survival with revascularization was estimated to be 
25.8% by 18F FDG-PET perfusion mismatch for the as-
sessment of viability, which is much lower than the cut-off 
values used by stress echocardiography and SPECT.[21] 
When PET was integrated into clinical patient management, 
a significant reduction in cardiac events was observed in 
patients with 18F-FDG PET-assisted management, according 
to randomized controlled trials.[22,23] This preliminary study 
did not address the impact of 18F-FDG PET on patient 
management, although all of these patients were diagnosed 
with significant coronary artery disease. Further research of 
incorporating 18F-FDG PET into patient management de-
serves to be investigated. 
Although 18F-FDG PET is regarded as the gold standard 
for the diagnosis of myocardial viability,[16] cardiac PET is 
not widely available as opposed to SPECT. Furthermore, 
the high cost of PET camera and cyclotron technology limit 
the extensive use of this technique in many clinical centers. 
This is the main reason in this study that we compared 
18F-FDG PET with SPECT and echocardiography to further 
clarify its clinical value, despite limited applications. In 
comparison with PET, SPECT still shows high diagnostic 
value at per-patient analysis with sensitivity of 90%. This 
highlights the fact that SPECT can be used as a reliable 
technique for assessment of myocardial viability due to its 
wide availability and low cost when 18F-FDG PET is not 
available. 
Invasive coronary angiography is the gold standard for 
the identification of obstructive coronary lesions, however, 
it lacks the sensitivity and specificity for the early detection 
of coronary artery disease, quantitative analysis of plaque 
composition and cardiac function assessment.[24,25] The most 
recently published PROSPECT (Providing Regional Ob-
servations to Study Predictors of Events in the Coronary 
Tree) trial highlights the value of non- or less-invasive im-
aging modalities to evaluate high-risk plaque for more ac-
curate risk stratification of patients with coronary artery 
disease, as invasive angiography was found to have poor 
predictive accuracy in identifying patients with high risk of 
developing acute cardiac events.[26] This has been confirmed 
by our study as well. Cardiac SPECT and PET showed 
more accurate assessment of myocardial viability in some 
patients with significant coronary stenosis which was only 
demonstrated as moderate coronary stenosis by invasive 
coronary angiography. The reason we used invasive coro-
nary angiography as the gold standard in this study is be-
cause all of the patients recruited were clinically diagnosed 
with significant coronary artery disease, thus, they were 
referred for invasive coronary angiography for the purpose 
of diagnosis and revascularization. Furthermore, we would 
like to determine the diagnostic value of invasive coronary 
angiography in risk stratification, in particular, the accuracy 
in predicting patients of developing cardiac events. In rou-
tine clinical practice, cardiac SPECT or PET is commonly 
used for the assessment of myocardial metabolism and via-
bility, while invasive coronary angiography is reserved for 
confirming disease extent and performing revascularization. 
This study further emphasises the clinical value of SPECT 
and PET for assessment of myocardial function while hig-
hlighting the limitations of lumen assessment by invasive 
coronary angiography. 
There are some limitations in this study that should be 
acknowledged. Firstly, the sample size is small. This is ei-
ther due to the number of patients who refused to participate 
in the study or due to the disease severity of CAD or unsta-
ble condition, therefore, most of the patients decided to un-
dergo revascularization treatment instead of further imaging 
assessment. Secondly, only patients with known or proven 
CAD were included in this study, thus, our results should be 
interpreted with caution, in particular the very high diagnos-
tic value of cardiac PET and SPECT in the assessment of 
myocardial viability. Lastly, although advances in nuclear 
cardiology imaging procedures have improved the ability to 
diagnose and treat cardiovascular conditions, there is a lack 
of patient-level data on radiation exposure over time from 
these procedures despite a rapid increase in their clinical use. 
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The dosimetry of different radiopharmaceuticals in nuclear 
cardiology may be quite different; therefore, it is necessary 
to be aware of the radiation dose associated with cardiac 
SPECT and PET procedures.[7] The effective dose of PET 
and SPECT ranges from 2 mSv to 30 mSv, depending on 
the type and activity of radiopharmaceuticals adminis-
tered.[10,27] Furthermore, CT-based attenuation correction is 
commonly performed during SPECT and PET examinations, 
thus, radiation dose associated with CT (although low-dose 
CT protocol is routinely used) should be considered as it 
contributes to the total radiation exposure to patients. All of 
the patients in this study are quite old (average age 60 years), 
however, attention should be paid to younger patients who 
undergo cardiac PET and SPECT examinations, with 
dose-reduction strategies being implemented whenever 
possible to minimize radiation dose. Another aspect that 
needs to be considered is the cost associated with cardiac 
SPECT and PET scans when compared to echocardiogra-
phy. Recently, echocardiography has been increasingly used 
in the diagnostic evaluation of cardiac structure and function 
due to dramatic improvements in technology, such as con-
trast echocardiography, 3D echocardiography and speckle 
tracking echocardiography.[28] Therefore, echocardiography 
still continues to play an important role in the current clini-
cal practice in the diagnosis of patients with coronary artery 
disease. 
In conclusion, 18F-FDG cardiac PET has high diagnostic 
value in the assessment of myocardial viability in patients 
with known coronary artery disease when compared to car-
diac SPECT and echocardiography. Further studies based 
on a large cohort are warranted to verify our preliminary 
results, and in particular, to determine the clinical impact of 
cardiac PET in patient management. 
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